7.00

0.00% +0.00

Metagenomi Inc (MGX)

Overview News Price History Discussions Forecast

Metagenomi Inc stock is currently priced at $7.00, with a 24-hour trading volume of 52,473. It has seen a +0.00% increased in the last 24 hours and a -15.15% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $7.03 pivot point. If it approaches the $6.79 support level, significant changes may occur.

Previous Close:

$7.00

Open:

$7.23

24h Volume:

52,473

Market Cap:

$262.25M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+6.87%

1M Performance:

-15.15%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$6.91

$7.23

52W Range:

$5.50

$12.74

Metagenomi Inc Stock (MGX) Company Profile

Name

Metagenomi Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

MGX's Discussions on Twitter

Metagenomi Inc Stock (MGX) Latest News

Research Analysts Offer Predictions for Metagenomi, Inc.'s Q2 2024 Earnings (NASDAQ:MGX) - Defense World

Defense World

Metagenomi, Inc. (NASDAQ:MGX) to Post Q2 2024 Earnings of ($0.69) Per Share, HC Wainwright Forecasts - MarketBeat

MarketBeat

HC Wainwright & Co. Initiates Coverage of Metagenomi (MGX) with Buy Recommendation - MSN

MSN

Metagenomi reports Q1 EPS ($1.19), consensus ($2.04) - TipRanks.com - TipRanks

TipRanks

Metagenomi's (MGX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

MarketBeat

Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results - GlobeNewswire

GlobeNewswire

Metagenomi Inc Stock (MGX) Financials Data

There is no financial data for Metagenomi Inc (MGX). Check out other stocks for more information.

Metagenomi Inc Stock (MGX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Novo Holdings A/S	10% Owner	Feb 09 '24	Buy	10.25	100,000	1,025,000	100,000

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. Genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat ("CRISPR")-associated transposases ("CASTs")).